Perrigo Company plc (NYSE:PRGO) Receives $19.33 Consensus Price Target from Brokerages

Perrigo Company plc (NYSE:PRGO) has been assigned an average rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $19.3333.

Several equities analysts have recently issued reports on PRGO shares. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Canaccord Genuity Group reduced their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th.

Perrigo Price Performance

PRGO stock opened at $11.21 on Friday. The firm has a 50 day moving average price of $10.83 and a 200-day moving average price of $12.84. Perrigo has a 52-week low of $9.23 and a 52-week high of $28.43. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -0.86, a PEG ratio of 1.33 and a beta of 0.52. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The firm had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the business earned $0.60 earnings per share. The business’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts forecast that Perrigo will post 2.14 EPS for the current fiscal year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Friday, May 29th will be given a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 10.4%. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Institutional Investors Weigh In On Perrigo

Institutional investors and hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its position in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares in the last quarter. UMB Bank n.a. increased its position in shares of Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after acquiring an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Perrigo during the fourth quarter valued at approximately $28,000. Finally, CWM LLC increased its position in shares of Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after acquiring an additional 1,527 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.